Will feds reclassify 'magic mushroom' therapies? Seattle doctor ramps up court battle
As psychedelic therapies make their way through the clinic, one Seattle doctor is taking his fight to change psilocybin’s status as a Schedule I substance to federal court.
Sunil Aggarwal petitioned the Ninth Circuit Court of Appeals on Thursday to review a decision by the Drug Enforcement Administration in September to leave psilocybin on the Schedule I list under the Controlled Substances Act. Schedule I drugs are considered to have a “high potential for abuse” with “no currently accepted medical use in treatment in the United States,” according to the CSA’s language.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.